celgosivir

inhibits glycoprotein processing & the growth of HIVs

Also Known As:

(1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate; (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate, hydrochloride; 6-O-butanoylcastanospermine; BuCast; MBI 3253; MBI-3253; MBI3253; MDL 28,574; MDL 28,574A; MDL 28574; MDL-28,574A; MDL-28574; MX 3253; MX-3253; MX3253; butanoic acid, octahydro-1,7,8-trihydroxy-6-indolizinyl ester, (1S-(1alpha,6beta,7alpha,8beta,8abeta))-; celgosivir HCl; celgosivir hydrochloride

Networked: 16 relevant articles (5 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indolizines: 3
      - Indolizidines: 2
        celgosivir: 16

Experts

1.	Ooi, Eng Eong: 6 articles (01/2018 - 12/2011)
2.	Vasudevan, Subhash G: 5 articles (03/2016 - 12/2011)
3.	Watanabe, Satoru: 5 articles (03/2016 - 12/2011)
4.	Rathore, Abhay P S: 4 articles (01/2016 - 12/2011)
5.	Sung, Cynthia: 4 articles (01/2016 - 12/2011)
6.	Chan, Kitti Wing-Ki: 2 articles (03/2016 - 01/2016)
7.	Low, Jenny G: 2 articles (03/2016 - 08/2014)
8.	Connolly, John E: 2 articles (01/2016 - 12/2011)
9.	Hibberd, Martin L: 2 articles (01/2016 - 08/2014)
10.	Khoo, Yok Moi: 2 articles (01/2016 - 10/2012)

Related Diseases

1.	Infections 12/01/2011 - "Significantly, celgosivir is effective in lethal challenge mouse models that recapitulate primary or secondary antibody-dependent enhanced DENV infection. " 10/01/2012 - "Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial." 02/01/2007 - "One such compound, celgosivir, is currently being evaluated in clinical trials against HCV infection, and encouraging phase IIa data have been disclosed. " 03/01/2016 - "Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy." 01/01/2016 - "A small, non-statistical trend towards better outcome on platelet nadir and difference between maximum and minimum hematocrit was observed in celgosivir-treated patients with secondary dengue infection. "
2.	Dengue (Dengue Fever) 01/01/2016 - "CELADEN was a randomized placebo-controlled trial of 50 patients with confirmed dengue fever to evaluate the efficacy and safety of celgosivir (A study registered at ClinicalTrials.gov, number NCT01619969). " 01/01/2016 - "Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients." 08/01/2014 - "Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial." 12/01/2011 - "Together the present study suggests that celgosivir, which has been clinically determined to be safe in humans, may be a valuable candidate for clinical testing in dengue patients." 01/01/2016 - "Optimization of the dosing regimen and patient stratification may enhance the ability of a clinical trial to demonstrate celgosivir activity in treating dengue fever based on hematological endpoints. "
3.	Hepatitis C 05/01/2004 - "Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C." 01/01/2021 - "Similarly, we also identified the drug Celgosivir, which has been successfully tested in cells infected with different types of viruses such as Dengue, Zika, Hepatitis C and Influenza. "
4.	Buruli Ulcer 10/31/2023 - "Oral drugs evaluated include sparfloxacin and acedapsone for leprosy; rifampicin, rifapentin and moxifloxacin for onchocerciasis; imatinib and levamisole for loiasis; itraconazole, fluconazole, ketoconazole, posaconazole, ravuconazole and disulfiram for Chagas disease, doxycycline and rifampicin for lymphatic filariasis; arterolane, piperaquine, artesunate, artemether, lumefantrine and mefloquine for schistosomiasis; ivermectin, tribendimidine, pyrantel, oxantel and nitazoxanide for soil-transmitted helminths including strongyloidiasis; chloroquine, ivermectin, balapiravir, ribavirin, celgosivir, UV-4B, ivermectin and doxycycline for dengue; streptomycin, amoxicillin, clavulanate for Buruli ulcer; fluconazole and isavuconazonium for mycoses; clarithromycin and dapsone for cutaneous leishmaniasis; and tribendimidine, albendazole, mebendazole and nitazoxanide for foodborne trematodiasis. "
5.	Cutaneous Leishmaniasis 10/31/2023 - "Oral drugs evaluated include sparfloxacin and acedapsone for leprosy; rifampicin, rifapentin and moxifloxacin for onchocerciasis; imatinib and levamisole for loiasis; itraconazole, fluconazole, ketoconazole, posaconazole, ravuconazole and disulfiram for Chagas disease, doxycycline and rifampicin for lymphatic filariasis; arterolane, piperaquine, artesunate, artemether, lumefantrine and mefloquine for schistosomiasis; ivermectin, tribendimidine, pyrantel, oxantel and nitazoxanide for soil-transmitted helminths including strongyloidiasis; chloroquine, ivermectin, balapiravir, ribavirin, celgosivir, UV-4B, ivermectin and doxycycline for dengue; streptomycin, amoxicillin, clavulanate for Buruli ulcer; fluconazole and isavuconazonium for mycoses; clarithromycin and dapsone for cutaneous leishmaniasis; and tribendimidine, albendazole, mebendazole and nitazoxanide for foodborne trematodiasis. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	castanospermine
3.	Ribavirin (Virazole)
4.	Chloroquine (Aralen)
5.	balapiravir
6.	Lovastatin (Mevacor)
7.	Prodrugs
8.	Glucosidases
9.	celgosivir
10.	glucosidase I

Related Therapies and Procedures

1.	Therapeutics